ABSTRACT
Introduction Peru is one of the most impacted countries due to COVID-19. Given the authorized use of hydroxychloroquine (HCQ), azithromycin (AZIT), and ivermectin (IVM), we aimed to evaluate their effectiveness alone or combined to reduce mortality among COVID-19 hospitalized patients without life-threatening illness.
Methods Retrospective cohort emulating a target trial, using nationwide data of mid- and high-level hospitals from the Peruvian Social Health Insurance 01/April/2020–19/July/2020. Patients 18 yo and above with PCR-confirmed SARS-CoV-2, and no life-threatening illness at admission were included. Five treatment groups (HCQ alone, IVM alone, AZIT alone, HCQ+AZIT, and IVM+AZIT within 48 hours of admission) were compared with standard of care alone. Primary outcome was all-cause mortality rate; secondary outcomes were all-cause death and/or ICU transfer, and all-cause death and/or oxygen prescription. Analyses were adjusted using inverse probability of treatment weighting. Propensity scores were estimated using machine learning boosting models. Weighted hazard ratios (wHR) were calculated using Cox regression.
Results Among 5683 patients, 200 received HCT, 203 IVM, 1600 AZIT, 692 HCQ+AZIT, 358 IVM+AZIT, and 2630 standard of care. HCQ+AZIT was associated with 84% higher all-cause death hazard compared to standard care (wHR=1.84, 95%CI 1.12-3.02). Consistently, HCQ+AZIT was also associated with higher death and/or ICU transfer (wHR=1.49, 95%CI 1.01-2.19), and death and/or oxygen prescription (wHR=1.70, 95%CI 1.07-2.69). HCQ only showed higher death and/or oxygen prescription hazard. No effect was found for AZIT or IVM+AZIT.
Conclusions Our study reported no beneficial effects of hydroxychloroquine, ivermectin, azithromycin. The HCQ+AZIT treatment seems to increase risk for all-cause death.
Funding Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Instituto de Evaluacion de Tecnologias en Salud e Investigacion (IETSI), EsSalud, Peru.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was classified with minimal risk of vulnerability for participants. In order to maintain the privacy of the patients, the data extraction was anonymized by the EsSalud informatics office before data manipulation or analysis. This target trial protocol was approved by EsSalud Institutional Review Board of COVID studies (91-SGRyGIS-DIS-IETSI-ESSALUD-2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Writing and wording of Introduction, Methods, Results and Discussion were updated to clarify reporting. Typos in table and in Methods (propensity score weighting calculation) were corrected. Figure 2 and 3 were edited to improve visualization. similarly, figures of Supplementary material were edited to improve visualization.
Data Availability
The data supporting the findings of this study are available in the IETSI EsSalud computer files, but restrictions apply to the availability of these data, which were used under the current study license and are therefore not publicly available. However, the data are available to the authors upon reasonable request and with the permission of IETSI EsSalud.